Abstract
Purpose: Inhibition of COX-2 enzymes is a frequently suggested mechanism for the beneficial effects of NSAIDs on carcinogenesis. The aim of this study was to explore the role of cumulative NSAID use on four common nonskin related cancers and modification by COX-2 G C genotype. Patients and methods: 7621 participants of The Rotterdam Study were included. In a mean follow up period of 10 years, 720 colorectal, lung, breast or prostate cancers occurred. Cumulative NSAID use was calculated per NSAID class. Individual associations of NSAID use and COX-2 G C genotype on cancer risk were explored with Cox proportional hazard models. Next, the association of NSAIDs and cancer stratified by COX-2 genotype was studied. Finally, the effect of combinations of NSAID use and COX-2 genotype on survival times was investigated. Conclusion: Our results confirm the protective effect of NSAID use on colorectal cancer. Individuals diagnosed with colorectal cancer who carry a COX-2 C allele and are on NSAIDs have an increased survival in comparison to non-users with the wild type .
Keywords: Anti-Inflammatory Agents, Non-Steroidal [MeSH], Cohort Study [MeSH], Cyclooxygenase 2 (inhibitors) [MeSH], Neoplasms [MeSH], Polymorphism, Single Nucleotide [MeSH]
Current Cancer Drug Targets
Title: Protective Effect of NSAIDs on Cancer and Influence of COX-2 C G Genotype
Volume: 8 Issue: 8
Author(s): C. Siemes, L. E. Visser, J. W.W. Coebergh, A. Hofman, A. G. Uitterlinden and B.H. Ch. Stricker
Affiliation:
Keywords: Anti-Inflammatory Agents, Non-Steroidal [MeSH], Cohort Study [MeSH], Cyclooxygenase 2 (inhibitors) [MeSH], Neoplasms [MeSH], Polymorphism, Single Nucleotide [MeSH]
Abstract: Purpose: Inhibition of COX-2 enzymes is a frequently suggested mechanism for the beneficial effects of NSAIDs on carcinogenesis. The aim of this study was to explore the role of cumulative NSAID use on four common nonskin related cancers and modification by COX-2 G C genotype. Patients and methods: 7621 participants of The Rotterdam Study were included. In a mean follow up period of 10 years, 720 colorectal, lung, breast or prostate cancers occurred. Cumulative NSAID use was calculated per NSAID class. Individual associations of NSAID use and COX-2 G C genotype on cancer risk were explored with Cox proportional hazard models. Next, the association of NSAIDs and cancer stratified by COX-2 genotype was studied. Finally, the effect of combinations of NSAID use and COX-2 genotype on survival times was investigated. Conclusion: Our results confirm the protective effect of NSAID use on colorectal cancer. Individuals diagnosed with colorectal cancer who carry a COX-2 C allele and are on NSAIDs have an increased survival in comparison to non-users with the wild type .
Export Options
About this article
Cite this article as:
Siemes C., Visser E. L., Coebergh W.W. J., Hofman A., Uitterlinden G. A. and Stricker Ch. B.H., Protective Effect of NSAIDs on Cancer and Influence of COX-2 C G Genotype, Current Cancer Drug Targets 2008; 8 (8) . https://dx.doi.org/10.2174/156800908786733414
DOI https://dx.doi.org/10.2174/156800908786733414 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bioinformatics Analysis of Functional Relations Between CNPs Regions
Current Bioinformatics Quinones Derived from Plant Secondary Metabolites as Anti-cancer Agents
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs as Cancer Biomarkers
MicroRNA Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Interactions of Vascular Endothelial Growth Factor and p53 with miR-195 in Thyroid Carcinoma: Possible Therapeutic Targets in Aggressive Thyroid Cancers
Current Cancer Drug Targets Pharmacogenetic Syndrome of Dihydropyrimidine Dehydrogenase Deficiency
Current Pharmacogenomics RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
Current Drug Metabolism Therapeutic Antibodies
Drug Design Reviews - Online (Discontinued) A2A Adenosine Receptor and its Modulators: Overview on a Druggable GPCR and on Structure-Activity Relationship Analysis and Binding Requirements of Agonists and Antagonists
Current Pharmaceutical Design Bis(2-aminoimidazolines) and Bisguanidines: Synthetic Approaches, Antiparasitic Activity and DNA Binding Properties
Current Medicinal Chemistry Serum Interleukin Levels and Insulin Resistance in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets The LPS-Pretreated MSCs Supply a Positive Microenvironment for Tumor Cell Proliferation and Clone Formation
Current Protein & Peptide Science Single Nucleotide Polymorphisms in Colitis-Associated Colorectal Cancer: A Current Overview with Emphasis on the Role of the Associated Genes Products
Current Drug Targets Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model
Current Pharmaceutical Biotechnology Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Current Drug Targets A Review on the Expression and Metabolic Features of Orphan Human Cytochrome P450 2S1 (CYP2S1)
Current Drug Metabolism Recent Advances in the Research and Development of B-Raf Inhibitors
Current Medicinal Chemistry The Type II Transmembrane Serine Protease, Matriptase-2: Possible Links to Cancer?
Anti-Cancer Agents in Medicinal Chemistry